TLR2 and cancer: Actually, TLR2 is activated by two poly-TLR agonists currently used or tested in cancer treatment, i.e., a Food and Drug Administration-approved live attenuated Mycobacterium bovis preparation of bacillus of the Calmette–Guerin strain and CADI-05, a polyantigenic vaccine containing heat-killed Mycobacterium indicus pranii currently undergoing clinical investigation.